<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>2 on MBofillRoig</title>
    <link>/publication_types/2/</link>
    <description>Recent content in 2 on MBofillRoig</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <copyright>&amp;copy; 2018</copyright>
    <lastBuildDate>Thu, 12 Oct 2017 00:00:00 +0100</lastBuildDate>
    
	<atom:link href="/publication_types/2/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Selection of composite binary endpoints in clinical trials</title>
      <link>/publication/bg_2017/</link>
      <pubDate>Thu, 12 Oct 2017 00:00:00 +0100</pubDate>
      
      <guid>/publication/bg_2017/</guid>
      <description>Abstract: The choice of a primary endpoint is an important issue when designing a clinical trial. It is common to use composite endpoints as a primary endpoint because it increases the number of observed events, captures more information and is expected to increase the power. However, combining events that have no similar clinical importance and have different treatment effects makes the interpretation of the results cumbersome and might reduce the power of the corresponding tests.</description>
    </item>
    
  </channel>
</rss>